5-Year Experience of Appendage Closure: More Evidence that Does Not Translate into Clinical Practice

The use of percutaneous left appendage closure increased 3.6-fold from 2011 to 2015, but this volume increase did not entail a significant uptrend of in-hospital events in this “real-world” population in Germany. However, can Germany be considered a real-world setting for Latin America? This question is warranted by the fact that there is no apparent volume increase for this technique in our region, which may be due to its cost or the lack of referral from clinicians to interventional cardiologists.

Resultados a 5 años del cierre de orejuela

For Germans, the most important predictors of in-hospital mortality were acute renal failure, pericardial effusion, and peri-procedural ischemic stroke.

The safety and efficacy of percutaneous left appendage closure have been demonstrated in randomized trials and prospective cohort studies, but data from a large number of daily clinical practice patients (at least from Germany) are missing.

This study included and analyzed 15,895 patients between 2011 and 2015. The annual number of procedures went up from 1347, in 2011, to almost four times that number (4932), in 2015. This increase was very significant (p < 0.001).


Read also: Five-Year Outcomes for Appendage Closure.


Patient characteristics changed over time, towards older age and prevalence of comorbidities such as heart failure, chronic obstructive pulmonary disease, and chronic renal insufficiency.

The most important independent predictors of in-hospital mortality were cancer (odds ratio [OR]: 2.49), heart failure (OR: 2.42), stroke (OR: 5.39), acute renal failure (OR: 13.28), pericardial effusion (OR: 5.65), and shock (OR: 45.11). The presence of acute renal failure in relation to this procedure, which uses very little contrast, is of note, while the increased mortality among patients with shock is absolutely unsurprising (even though none of us would even dream of conducting an appendage closure in such a setting).

Conclusion

The use of left appendage closure increased 3.6-fold from 2011 to 2015, with a nonsignificant uptrend of mortality. This was all in a setting where treated patients were significantly more ill. The most important predictors of in-hospital mortality were acute renal failure, pericardial effusion, and peri-procedural stroke.

Original title: 5-Year Experience of In-HospitalOutcomes After Percutaneous Left Atrial Appendage Closure in Germany.

Reference: Lukas Hobohm et al. J Am Coll Cardiol Intv 2019;12:1044–52.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...